U.S. pharmaceutical company Zafgen which received technology from Chong Kun Dang reached NASDAQ listing value of about $ 400 million

U.S. pharmaceutical company Zafgen which received the technique of severe obesity treatment `CKD-732` (ingredient belolanip) from Chong Kun Dang recently listed in Nasdaq, and reached listing value of about $ 400 million (411 billion won). The technology of 'CKD-732` was exported to Zafgen in 2009 on condition of receiving export deposit, milestone and royalty. 

Severe obesity treatment `CKD-7...